Advertisement

Clinicopathological Features, Recurrence Patterns, and Prognosis of Pancreatic Adenocarcinoma with Normal Serum CA19-9. A Consecutive Series of 154 Cases from a Single Institute

  • Yajie Zhao
  • Chengfeng WangEmail author
Original Article
  • 24 Downloads

Abstract

Background

Serum levels of CA19-9 correlate with recurrence and survival in patients with pancreatic adenocarcinoma; however, little is known about the features and prognosis of pancreatic adenocarcinoma with normal CA19-9 levels.

Method

Patients with pancreatic adenocarcinoma (n = 806) were split into two groups with normal (≤ 37 U/mL) and elevated (> 37 U/mL) CA19–9. The clinicopathological features, survival, and recurrence patterns were compared between two groups. We also sought to identify factors that best predicted prognosis in pancreatic adenocarcinoma with normal CA19-9 levels, to assist in the selection of the most effective adjuvant treatment.

Results

Pancreatic adenocarcinoma with normal CA19-9 were less likely to have lymph node metastasis, angiolymphatic invasion, intrapancreatic neural invasion, anterior serosal invasion, and invasion of the surrounding tissue/organ (distal bile duct, duodenum, or splenic artery or vein). Following propensity-score matching, pancreatic adenocarcinoma with normal CA19-9 levels (≤ 37 U/ml) were associated with significantly superior overall survival following resection. Moreover, the CA19-9 ≤ 37 U/mL group demonstrated a significantly lower rate of local recurrence (35.57% vs. 52.35%, p = 0.004), distant recurrence (42.95% vs. 60.4%, p = 0.003), and mixed recurrence (5.37% vs. 29.53%, p < 0.000) compared with the CA19–9 > 37 U/mL group. Multivariate analysis suggested that angiolymphatic invasion, lymph node metastases, and tumor size > 3 cm were independent prognostic factors for pancreatic adenocarcinoma with normal CA19-9. Survival analyses suggested that post-op chemoradiotherapy or chemotherapy were associated with more favorable outcomes.

Conclusions

Pancreatic adenocarcinoma with normal pretreatment CA19-9 levels (≤ 37 U/ml) were characterized by better biological characteristics, reduced rates of recurrence, and longer overall survival. Moreover, optimal adjuvant therapy should be performed after surgery.

Keywords

Prognosis Multivariate analysis Propensity score Pancreatic adenocarcinoma Regression analysis 

Notes

Authors Contributions

Yajie Zhao took part in collecting clinical data, reading literature and writing manuscript. Chengfeng Wang was involved in co-supervision, final editing/critical revisions, interpretation/important intellectual content.

Funding information

This work was supported by CAMS Innovation Fund for Medical Sciences (CIFMS) grant number 2016-I2M-1-001.

Compliance with Ethical Standards

This study was approved by the Institutional Ethnic Committee on Scientific Research of National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, and informed consent was obtained from all patients in this study.

Conflict of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper. And CAMS Innovation Fund did not lead to any conflict of interests regarding the publication of this manuscript.

References

  1. 1.
    Amanam I, Chung V. Targeted therapies for pancreatic cancer. Cancers, 2018;10(2):97.CrossRefGoogle Scholar
  2. 2.
    Ellison LF, Wilkins K. An update on cancer survival. Health Rep.2010;21(3):55–60Google Scholar
  3. 3.
    Yeole BB, Kumar AV. Population-based survival from cancers having a poor prognosis in Mumbai (Bombay), India. Asian Pac J Cancer Prev. 2004; 5(2):175–182Google Scholar
  4. 4.
    Koprowski H, Steplewski Z, Mitchell K, et al. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genetics 1979; 5:957–71.CrossRefGoogle Scholar
  5. 5.
    Safi F, Beger HG, Bittner R, Buchler M, Krautzberger W. CA19-9 and pancreatic adenocarcinoma. Cancer 1986; 57: 779–83.CrossRefGoogle Scholar
  6. 6.
    Magnani J, Nilsson B, Brockhaus M, et al. A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopenteose II. J Biological Chem 1982; 257:14365–9.Google Scholar
  7. 7.
    Vestergaard EM, Hein HO, Meyer H, Grunnet N, Jørgensen J, Wolf H, Orntoft TF. Reference values and biological variation for tumor marker CA19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population. Clin Chem. 1999;45(1):54–61.Google Scholar
  8. 8.
    Kijima H, Kashiwagi H, Dowaki S, Ohtani Y, Tobita K, Matsubayasi H, Ajioka Y, Watanabe H, Tsuchida T, Yamazaki H, Nakamura M, Ueyama Y, Tanaka M, Makuuchi H. Stromal sialyl Le(a) expression is correlated with vascular invasion of human gallbladder adenocarcinoma. Int J Oncol. 2000;17(1):55–60.Google Scholar
  9. 9.
    Matsumoto S. Cimetidine and survival with colorectal cancer. Lancet. 1995;346(8967):115.CrossRefGoogle Scholar
  10. 10.
    Matsumoto S, Imaeda Y, Umemoto S, Kobayashi K, Suzuki H, Okamoto T. Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis-X and sialyl Lewis-A epitope expression on tumor cells. Br J Cancer. 2002;86(2):161–7.CrossRefGoogle Scholar
  11. 11.
    Yokoigawa N, Takeuchi N, Toda M, et al. Enhanced production of interleukin 6 in peripheral blood monocytes stimulated with mucins secreted into the bloodstream. Clin Cancer Res. 2005; 11(17):6127–32.CrossRefGoogle Scholar
  12. 12.
    Yokoigawa N, Takeuchi N, Toda M, et al. Overproduction of PGE2 in peripheral blood monocytes of gastrointestinal cancer patients with mucins in their bloodstream. Cancer Lett. 2007; 245(1–2):149–55.CrossRefGoogle Scholar
  13. 13.
    Kannagi R, Izawa M, Koike T, Miyazaki K, Kimura N. Carbohydrate-mediated cell adhesion in cancer metastasis and angiogenesis. Cancer Sci. 2004;95(5):377–84.CrossRefGoogle Scholar
  14. 14.
    Honn KV, Tang DG, Crissman JD. Platelets and cancer metastasis: a causal relationship? Cancer Metastasis Rev. 1992;11(3–4):325–51.CrossRefGoogle Scholar
  15. 15.
    Waraya M, Yamashita K, Katagiri H. Preoperative serum CA19-9 and dissected peripancreatic tissue margin as determiners of long-term survival in pancreatic cancer. Ann Surg Oncol 2009.16(5):1231–1240CrossRefGoogle Scholar
  16. 16.
    Smith RA, Bosonnet L, Ghaneh P. Preoperative CA19-9 levels and lymph node ratio are independent predictors of survival in patients with resected pancreatic ductal adenocarcinoma. Dig Surg 2008.25(3):226–232CrossRefGoogle Scholar

Copyright information

© The Society for Surgery of the Alimentary Tract 2019

Authors and Affiliations

  1. 1.Department of Pancreatic and Gastric surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina

Personalised recommendations